Fluorinated quinolones
Tóm tắt
Từ khóa
Tài liệu tham khảo
Smith JT. Chemistry and mode of action of 4-quinolone agents. Fortschr Antimikrob Chemother 1984:3–5:493–508.
Shah PM. Gyrase inhibitors - a new group of antibacterial agents. Quinolones Bull October 1984;1.
Schentag JJ, Domagala JM. Structure-activity relationships with the quinolone antibiotics. Res Clin Forums 1985;7:9–15.
Wentland MP, Bailey DM, Cornett JB, et al. Novel amino-substituted 3-quinolone carboxylic acid antibacterial agents. J Med Chem 1984;27:1103–8.
Mahmood F, Mahmood NH, Holmes WH. Antibacterial action of quinolones onE. coli. Structure-activity relationships. Zentralbl Bakteriol Mikrobiol Hyg [B] 1980:329–35.
Abstracts of the 14th International Congress of Chemotherapy, Kyoto, June 23–28, 1985. Kyoto: International Society of Chemotherapy, 1985.
Crumplin GC, Midgley JM, Smith JT. Mechanism of action of nalidixic acid and its congeners. Top Antibiot Chem 1980;3:1138.
Crumplin GC, Smith JT. Nalidixic acid: an antibacterial paradox. Antimicrob Agents Chemother 1975;8:251–61.
Kayser FH. The quinolones: mode of action and mechanism of resistance. Res Clin Forums 1985;7:17–27.
Geliert M, Mizuuchi K, O'Dea MH, et al. DNA gyrase. an enzyme that introduces superhelical turns into DNA. Proc Natl Acad Sci USA 1976;73:3872–8.
Geliert M, O'Dea MH, Otoh T, et al. Novobiocin and coumermycin inhibit DNA supercoiling by DNA gyrase. Proc Natl Acad Sci USA 1976;73:4474–8.
Sato K, Hirai K, Inone M. et al. Antibacterial activity of ofloxacin and its mode of bactericidal action. In ref. 151:51–8.
Smith JT, Ratcliffe NT. Ciprofloxacin and ofloxacin possess an extrabactericidal mechanism absent from other 4-quinolone antibacterial agents. In ref. 151:45–50.
Shen LL, Pernet AG. Mechanism of inhibition of DNA gyrase by analogues of nalidixic acid: the target of the drug is DNA. Proc Natl Acad Sci USA 1985;82:307–11.
Chin NX, Neu HC. Ciprofloxacin, a quinolone carboxylic acid compound active against aerobic and anaerobic bacteria. Antimicrob Agents Chemother 1984;25:319–26.
Van Caekenberghe DL, Pattyn SR.In vitro activity of ciprofloxacin compared with those of other new fluorinated piperazinyl-substituted quinoline derivatives. Antimicrob Agents Chemother 1984;25:518–21.
Goossens H, De Mol P, Coignau H, et al. Comparativein vitro activities of azthreonam, ciprofloxacin, norfloxacin, ofloxacin, HR 810, RU 28965 and other agents against enteropathogens. Antimicrob Agents Chemother 1985;27:388–92.
Cullmann W, Stieglitz M, Baars B, Opferkuch W. Comparative evaluation of recently developed quinolone compounds, with a note on the frequency of resistant mutants. Chemotherapy 1985;31:19–28.
Felmingham D., O'Hare M. D., Gruneberg RN, et al. The comparative activity of 11 quinoline antibiotics againstN. gonorrhoeae. In: Spitzky KH, Karrer K, eds. Proceedings of the 13th International Congress of Chemotherapy, Vienna, 1983. Vienna: Egermann, 1983: Abstract PS 4.6/7-7.
Wise R, Andrews JM, Edwards LJ.In vitro activity of Bay 09867, a new quinoline derivative, compared with those of other antimicrobial agents. Antimicrob Agents Chemother 1983;23:559–64.
Cornett JB, Wagner RB, Dobson RA.In vitro andin vivo antibacterial activity of the fluoroquinolone WIN 49375. Antimicrob Agents Chemother 1985;27:4–10.
Noone P. Sisomicin, netilmicin and dibekacin. A review of their antibacterial activity and therapeutic use. Drugs 1983;27:548–78.
Chin NX, Neu HC.In vitro activity of enoxacin, a new quinolone carboxylic acid, compared with those of norfloxacin, new betalactams, aminoglycosides and trimethoprim. Antimicrob Agents Chemother 1983;24:754–63.
Righter J.In vitro activity of ciprofloxacin, azthreonam and ceftazidime againstS. marcescens andP. aeruginosa. Eur J Clin Microbiol 1984;3:368–9.
Bauernfeind A. Quinolones; active againstPseudomonas or justP. aeruginosa? Quinolones Bull June 1985;1:3–4.
Abstracts of the 24th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington DC, October 8–10, 1984. Washington DC: American Society for Microbiology, 1984.
Scribner R, Weber A, Marks MI.In vitro activity of ofloxacin against bacterial isolates from paediatric patients. In ref. 151:14–21.
Chartrand SA, Scribner RK, Weber AH, Welch DF, Marks MI.In vitro activity of CI-919, an oral antipseudomonal compound. Antimicrob Agents Chemother 1983;123:658–63.
Bauernfeind A, Petermüller CH. Vergleich der antibakteriellen Profile von Ciprofloxacin, Norfloxacin, Pefloxacin, Ofloxacin, Enoxacin, Pipemidsäure und Nalidixinsäure. Fortschr Antimikrob Chemother 1985;3–5;531–48.
Van Landuyt HW, Rummens JL, Boelaert J, Lambert AM.In vitro activity of ofloxacin, compared with six other quinolones and five beta-lactams. In ref. 151:26–30.
Goodman LJ, Fliegelman RM, Trenholme GM, et al. Comparativein vitro activity of ciprofloxacin againstCampylobacter spp. and other bacterial enteric pathogens. Antimicrob Agents Chemother 1984;25:504–6.
Barry AL, Jones RN, Thornsberry C, Ayers LW, Gerlach EH, Sommers HH. Antibacterial activities of ciprofloxacin, norfloxacin, oxolinic acid, cinoxacin and nalidixic acid. Antimicrob Agents Chemother 1984;25:633–7.
Eliopoulos GM, Gardella A, Moellering RC.In vitro activity of ciprofloxacin, a new carboxyquinoline anti-microbial agent. Antimicrob Agents Chemother 1984;25:331–5.
Bauernfeind A, Petermüller C.In vitro activity of ciprofloxacin, norfloxacin and nalidixic acid. Eur J Clin Microbiol 1983;2:111–5.
Siporin C, Towse G. Enoxacin: world widein vitro-activity against 22451 clinical isolates. J Antimicrob Chemother 1984;14 (suppl C):47–55.
King A, Shannon K, Phillips I. Thein vitro activity of ciprofloxacin and nalidixic acid. J Antimicrob Chemother 1984;13:325–31.
Goldstein EJ, Citron DM. Comparative activity of the quinolones against anaerobic bacteria isolated at community hospitals. Antimicrob Agents Chemother 1985;27:657–9.
Suther VL, Kwok YY, Bulkacz J. Comparative activity of ciprofloxacin against anaerobic bacteria. Antimicrob Agents Chemother 1985;27:427–8.
Isaacson DM, Foleno B.In vitro activity of a new quinolone antimicrobial, ofloxacin, againstLegionella and other selected respiratory pathogens. In ref. 151:59–62.
Felmingham D, O'Hare MD, Robbins MJ, et al. Comparativein vitro study with 4-quinolone anti-microbials. Drugs Exp Clin Res 1985;11:317–29.
Borobio MV, Perea EJ. Effect of inoculum, pH and medium on the activity of ciprofloxacin against anaerobic bacteria. Antimicrob Agents Chemother 1984;25:342–3.
Greenwood D, Laverick A. Activities of newer quinolones againstLegionella group organisms. Lancet 1983;2:279–80.
Ruckdeschel G, Ehret W, Ahl A. Susceptibility ofLegionella spp. to quinolone derivates and related organic acids. Eur J Clin Microbiol 1984;3:373.
Roudier G, Bornstein N, Fleurette J. Susceptibility ofLegionella spp. to pefloxacin and five other quinolone antibiotics. In: Spitzky KH, Karrer K, eds. Proceedings of the 13th International Congress of Chemotherapy, Vienna, 1983. Vienna: Egermann, 1983: Abstract PS 4.6/4-13.
Heessen FW, Muyjens HL.In vitro activity of ciprofloxacin, norfloxacin, pipemidic acid, cinoxacin and nalidixic acid againstC. trachomatis. Antimicrob Agents Chemother 1984;25:123–4.
Ridgway GL, Mumtaz G, Gabriel FC, Oriel JD. The activity of ciprofloxacin and other 4-quinolones againstC. trachomatis and mycoplasmasin vitro. Eur J Clin Microb 1984;3:344–6.
Freeman S, Wormuth J, Cornett J.In vitro activity of amifloxacin againstC. trachomatis andU. urealyticum. Eur J Clin Microbiol 1985;4:515–6.
Van Roosbroeck RJ, Provinciael D, Van Caeckenberghe DL. Activity of the newer quinolones againstC. trachomatis. Br J Vener Dis 1984;60:350.
Bailey JM, Heppleston C, Richmond S. Comparison of thein vitro activities of ofloxacin and tetracycline againstC. trachomatis as assessed by indirect immuno-fluorescence. Antimicrob Agents Chemother 1984;26:13–6.
Hart CA, How SJ, Hobson J. Activity of ciprofloxacin against genital tract pathogens. Br J Vener Dis 1984;60:316–8.
Abstracts of the 4th Mediterranean Congress of Chemotherapy, Rhodos, October 19–25, 1984.
Knothe H.In vitro activity of gyrase inhibitors. Quinolones Bull October 1984;1.
Gaya H, Chadwick MV.In vitro activity of ciprofloxacin againstMycobacteria. Eur J Clin Microbiol 1984;4:345–7.
Shrire L, Saunders J, Traynor R, Koornhof HJ. A laboratory assessment of ciprofloxacin and comparable antimicrobial agents. Eur J Clin Microbiol 1984;3:328–32.
Van der Auwera P, De Moor G, Lacroix G, Mambour A, Rossion N, Schuyteneer F.In vitro activity of enoxacin compared with norfloxacin and amikacin. Eur J Clin Microbiol 1985;4:55–8.
Wise R, Andrews JM, Danks G.In vitro activity of enoxacin, a new quinolone derivative compared with that of other antimicrobial agents. J Antimicrob Chemother 1984;13:237–44.
Duval J, Acar JF, Bergogne-Berezin E.In vitro activity of pefloxacin against 3422 hospital strains. In: Spitzky KH, Karrer K, eds. Proceedings of the 13th International Congress of Chemotherapy, Vienna, 1983. Vienna: Egermann, 1983: Abstract PS 4.6/4-2.
Thabaut A, Durosoir JL. Activité antibactérienne comparée in vitro de la péfloxacine, de l'acide nalidixique, de l'acide pipémidique et de la fluméquine. Pathol Biol (Paris) 1982;30:394–7.
John JF, Twitty JA. Amifloxacin activity against well-defined gentamicin resistant Gram-negative bacteria. Antimicrob Agents Chemother 1984;26:781–4.
Pohlod DJ, Saravolatz LD.In vitro susceptibility of 393 recent clinical isolates to WIN 49375, cefotaxime, tobramycin and piperacillin. Antimicrob Agents Chemother 1984;25:377–9.
Muytjens HL, Van de Ros-van de Repe J, Van Veldhuizen G. Comparative activities of ciprofloxacin, norfloxacin, pipemidic acid and nalidixic acid. Antimicrob Agents Chemother 1983;24:302–4.
Hoogkamp-Korstanje JA. Comparativein vitro activity of five quinolone derivatives and five other antimicrobial agents used in oral therapy. Eur J Clin Microbiol 1984;3:333–8.
Reeves DS, Bywater MJ, Holt HA, White LO.In vitro studies with ciprofloxacin, a new 4-quinolone compound. J Antimicrob Chemother 1984;13:333–46.
Duncan IB, Skulnick M, Marshall PW.In vitro activity of enoxacin against aminoglycoside resistant Gram-negative bacilli and other clinical isolates. J Antimicrob Chemother 1984;14(suppl C):1–6.
Seibert G, Kiesel N, Limbert M. Die antibakterielle Aktivitätin vitro von Ofloxacin im Vergleich mit anderen oral verabreichbaren antimikrobiellen Substanzen bei Ampicillin resistenten klinische Isolaten. Arzneim Forsch/Drug Res 1984;34:1552–4.
Roy C, Foz A, Segura C, et al. Activity of ciprofloxacin againstP. aeruginosa and ampicillin-resistant Entero-bacteriaceae. Infection 1983;11:326–8.
Seibert G, Limbert M, Kiesel N. Comparison of the antibacterial invitro andin vivo activity of ofloxacin and nalidixic acid analogues. Eur J Clin Microbiol 1983;2:548–53.
Bauernfeind A, Ullmann U.In vitro activity of enoxacin, ofloxacin, norfloxacin and nalidixic acid. J Antimicrob Chemother 1984;14(suppl C):33–7.
Olsson-Liljequist B.In vitro activity of ciprofloxacin againstBacteroides, H. influenzae andB. catarrhalis. Eur J Clin Microbiol 1984;3:370–1.
Clarke AM, Zemcov SJ, Campbell ME.In vitro activity of pefloxacin compared with enoxacin, norfloxacin, gentamicin and new betalactams. J Antimicrob Chemother 1985;15:39–44.
Peeters M, Van Dyck E, Piot P.In vitro activities of the spectinomycin analog U-63366 and four quinolone derivatives againstN. gonorrhoeae. Antimicrob Agents Chemother 1984;26:608–9.
Hawkey PM, Hawkey CA. Comparativein vitro activity of quinolone carboxylic acids againstProteeae. J Antimicrob Chemother 1984;14:485–9.
Zeiler HJ, Metzger KG, Schacht P, Groke K. Assessment of thein vitro andin vivo activity of ciprofloxacin measured against current standards of therapy. Drugs Exp Clin Res 1985;11:343–50.
Iravani A, Welty GS, Newton BR, Richard GA. Effects of changes in pH. medium and inoculum size on thein vitro activity of amifloxacin against urinary isolates ofS. saprophyticus andE. coli. Antimicrob Agents Chemother 1985;27:449–51.
Zeiler HJ. Influence of pH and human urine on the antibacterial activity of ciprofloxacin, norfloxacin and ofloxacin. Drugs Exp Clin Res 1985;11:335–8.
Efstriatiou E, Sahin A, Giamarellou H.In vitro studies with ciprofloxacin, a nalidixic acid analogue. In: Spitzky KH, Karrer K, eds. Proceedings of the 13th International Congress of Chemotherapy, Vienna, 1983. Vienna: Egermann, 1983: Abstract PS 4.6/7-3.
Neu HC. The effects of cations upon the activity of quinolone agents. Quinolones Bull April 1985:1.
Bauernfeind A, Petermüller C, Danninger J. Selection of mutants with increased MIC by pefloxacin, ofloxacin, norfloxacin and ciprofloxacin inP. aeruginosa. In ref. 151:36–44.
Sanders CS, Sanders WE, Goering RV, Werner V. Selection of multiple antibiotic resistance by quinolones, β-lactams and aminoglycosides with special reference to cross-resistance between unrelated drug classes. Antimicrob Agents Chemother 1984;26:797–801.
Crook SM, Selkon JB, McLardy Smith PD. Clinical resistance to long-term oral ciprofloxacin. Lancet 1985;1:1275.
Smith JT. Mutational resistance to 4-quinolone antibacterial agents. Eur J Clin Microbiol 1984;3:347–50.
Abstracts of the 25th Interscience Conference on Antimicrobial Agents and Chemotherapy, Minneapolis, September 29-October 2, 1985. Washington DC: American Society for Microbiology, 1985.
Brumfitt W, Franklin J, Grady D, Hamilton-Miller JM, Iliffe A. Changes in the pharmacokinetics of ciprofloxacin and fecal flora during administration of a 7-day course to human volunteers. Antimicrob Agents Chemother 1984;26:757–61.
Gonzalex MA, Uribe F, Moisen SD, et al. Multiple-dose pharmacokinetics and safety of ciprofloxacin in normal volunteers. J Antimicrob Chemother 1984;26:741–4.
Aronoff GE, Kenner GH, Sloan RS, Pottratz ST. Multiple-dose ciprofloxacin kinetics in normal subjects. Clin Pharmacol Ther 1984;36:384–8.
Wise R, Lockley RM, Webberly M, Dent J. Pharmacokinetics of intravenously administered ciprofloxacin. Antimicrob Agents Chemother 1984;26:208–10.
Höffler D, Dalhoff A, Gau W, Beermann D, Michl A. Dose- and sex-independent disposition of ciprofloxacin. Eur J Clin Microbiol 1984;3:363–6.
Wingender W, Graefe KH, Gau W, Förster D, Beermann D, Schacht P. Pharmacokinetics of ciprofloxacin after oral and intravenous administration in healthy volunteers. Eur J Clin Pharmacol 1984;3:355–9.
Crump B, Wise R, Dent J. Pharmacokinetics and tissue penetration of ciprofloxacin. Antimicrob Agents Chemother 1983;24:784–6.
Ledergerber B, Bettex JD, Joos B. Effect of standard breakfast on drug absorption and multiple-dose pharmacokinetics of ciprofloxacin. Antimicrob Agents Chemother 1985;27:350–2.
Höffler G, Lode H, Prinzing C. Pharmacokinetics of ciprofloxacin after oral and parenteral administration. Antimicrob Agents Chemother 1985;27:375–9.
Höffler G, Lode H, Prinzing C. Pharmakokinetik von Ciprofloxacin. Klin Wochenschr 1985;63(suppl 4):365.
Adhami ZN, Wise R, Weston D, Crump B. The pharmacokinetics and tissue penetration of norfloxacin. J Antimicrob Chemother 1984;13:87–92.
Hughes PJ, Webb DB, Asscher AW. Pharmacokinetics of norfloxacin in patients with impaired kidney function — some preliminary results. J Antimicrob Chemother 1984;13(suppl B):55–7.
Fillastre JP, Hannedouche T, Leroy A. Pharmacokinetics of norfloxacin in renal failure. J Antimicrob Chemother 1984;14:439.
Wolff M, Regnier B, Daldoss C, Nkam M, Vachon F. Penetration of pefloxacin into CSF of patients with meningitis. Antimicrob Agents Chemother 1984;26:289–91.
Montay G, Goueffon Y, Roquet F. Absorption, distribution, metabolic fate and elimination of pefloxacin mesylate in mice, rats, dogs, monkeys and humans. Antimicrob Agents Chemother 1984;25:463–72.
Gaillot J, Frydman A, LeRoux Y, et al. Pharmacokinetics of pefloxacin in man during a repeated treatment with intravenous infusion. In: Spitzky KH, Karrer K, eds. Proceedings of the 13th International Congress of Chemotherapy, Vienna, 1983. Vienna: Egermann, 1983: Abstract PS 4.6/4-5.
Barre J, Houin G, Tillement JP. Dose-dependent pharmacokinetic study of pefloxacin, a new antibacterial agent, in humans. J Pharm Sci 1984;73:1379–82.
Lockley MR, Wise R, Dent J. The pharmacokinetics and tissue penetration of ofloxacin. J Antimicrob Chemother 1984;14:647–52.
Katsu M, Saito A. An overview of experimental and clinical results in Japan with ofloxacin, a unique new antibacterial agent. In ref. 133:5–7.
Nakano H, Nihira H, Kamiya A, Hori R. Influence of renal impairment on multiple-dose pharmacokinetics of ofloxacin. In ref. 151:63–8.
Wise R, Lockley R, Webberly M, et al. The pharmacokinetics and tissue penetration of enoxacin and norfloxacin. J Antimicrob Chemother 1984;14(suppl C):75–81.
Brogard JM, Jehl F, Arnaund JP, et al. Ciprofloxacine: évaluation de son élimination biliaire chez l'homme. Schweiz Med Wochenschr 1985;115:448–53.
Boerema JB, Dalhoff A, Debruyne FM. Ciprofloxacin distribution in prostatic tissue and fluid following oral administration. Chemotherapy 1985;31:13–8.
Hoogkamp-Kostanje JA, Van Oort HJ, Schipper JJ, Van der Wal T. Intraprostatic concentration of ciprofloxacin and its activity against urinary pathogens. J Antimicrob Chemother 1984;14:641–5.
Boerema JB, Debruyne FM, Dalhoff A. Intraprostatic concentrations of ciprofloxacin after intravenous administration. Lancet 1984;2:695–6.
Höffken G, Borner K, Glatzel PD. Reduced enteral absorption of ciprofloxacin in the presence of antacids. Eur J Clin Microbiol 1984;4:345.
Pangon B. Gehanno P, Daldoss C, et al. Tissue diffusion of pefloxacin, study in man. In: Spitzky KH, Karrer K, eds. Proceedings of the 13th International Congress of Chemotherapy, Vienna 1983. Vienna: Egermann, 1983: Abstract PS 4.6/4-7.
Morel C, Vergnaud M. Langeard MM, et al. Peflox-acin-diffusion into the bronchial mucus. In: Spitzky KH, Karrer K, eds. Proceedings of the 13th International Congress of Chemotherapy, Vienna, 1983. Vienna: Egermann, 1983: Abstract PS 4.6/4-8.
Bergogne-Berezin E. Pharmacokinetic parameters of quinolones in respiratory tract infections. Quinolones Bull 1985;1:17–9.
Abstracts of the 2nd European Congress of Clinical Microbiology, Brighton, September 1–5, 1985. Brighton: European Society of Clinical Microbiology, 1985.
Wolf R, Eberl R, Dunky A, et al. The clinical pharmacokinetics and tolerance of enoxacin in healthy volunteers. J Antimicrob Chemother 1984;14(suppl C):63–9.
Wijnands WJ, Van Herwaarden CL, Vree TB. Enoxacin raises plasma theophylline concentrations. Lancet 1984;2:108–9.
Maessen FP, Teengs JP, Baur C, et al. Quinolones and raised plasma concentrations of theophylline. Lancet 1984;2:530.
Ohno H, Inage F, Akahane K, et al. Acute toxicity study of ofloxacin, a new synthetic antibacterial agent, in mice, rats, dogs and monkeys. In ref. 133:123.
Kato M, Ohno H, Yoshida M, et al. Twenty-six weeks chronic oral toxicity of ofloxacin, a new synthetic antibacterial agent, in rats. In ref. 133:125–6.
Furuhama K, Akahane K, Kato M, et al. Ten-day oral nephrotoxicity study of ofloxacin in rabbits. In ref. 133:126.
Kojima H, Hirohashi M, Sakurai T, et al. General pharmacology of ofloxacin. In ref. 133:127–8.
Shimada H, Ebine Y, Kurosawa Y, et al. Mutagenicity studies of ofloxacin, a new antibacterial drug. In ref. 133:128–9.
Norden CW, Shinners E. Ciprofloxacin as therapy for experimental osteomyelitis caused byP. aeruginosa. J Infect Dis 1985;151:291–4.
Boscia JA, Kobasa WD, Kaye D. Oral enoxacin vs parenteral cefoperazone in the treatment of experimental endocarditis. Res Clin Forums 1985;7:55–61.
Strunk RW, Gratz JC, Maserati R, Scheid WM. Comparison of ciprofloxacin with azlocillin plus tobramycin in the therapy of experimentalP. aeruginosa endocarditis. Antimicrob Agents Chemother 1985;28:428–32.
Katsu M, Saito A. An overview of experimental and clinical result in Japan with ofloxacin, a unique new antibacterial agent. In ref. 133:8–9.
Modak S, Stanford J, Friedländer J, et al. Control of burnwound infections by pefloxacin and its silver derivative. Burns 1983;10:170–8.
Matsuda S, Kashiwagura T, Kokuho K, et al. Experimental and clinical studies of ofloxacin in the fields of obstetrics and gynaecology. In ref. 133:94.
Cho N, Koh Y, Hara Y, et al. Fundamental and clinical evaluation of ofloxacin in the obstetric and gynaecological fields. In ref. 133:95.
Seki K, Hagashi S. Clinical experience of ofloxacin. In ref. 133:96.
Shah PM, Frech K. Clinical experience with quinolones-overview. Quinolones Bull 1985;1:19–22.
Ramirez CA, Bran JL, Mejia CR, Garcia JF. Open prospective study of the clinical efficacy of ciprofloxacin. Antimicrob Agents Chemother 1985;28:128–32.
Anonymous. Ofloxacin, broad spectrum antibacterial agent Tokyo: Excerpta Medica, 1984:7–8, 81–2, 108–12, 114–5.
Wolff M., Vittecoq D., Regnier B, et al. Preliminary trial of pefloxacin in the treatment of urinary tract infections and in seriously ill patients treated in hospital. In: Spitzky KH, Karrer K, eds. Proceedings of the 13th International Congress of Chemotherapy, Vienna 1983. Vienna: Egermann, 1983: Abstract PS 4.6/4-14.
Benard Y, Lemenager J, Morel C. Biochemical evaluation of pefloxacin in infectious bronchopulmonary disease. In: Spitzky KH, Karrer K, eds. Proceedings of the 13th International Congress of Chemotherapy, Vienna 1983. Vienna: Egermann, 1983: Abstract PS 4.6/4-9.
Shah PM. Ciprofloxacin in the treatment of cystic fibrosis. Quinolones Bull October 1984:1.
Michalsen H, Stiris T, Bergan T. Peroral ciprofloxacin in the treatment of infection withPs. aeruginosa in patients with CF. 13th Annual Meeting of the European Working Group for CF, Jerusalem, 1985. Jerusalem: European Working Group for CF, 1985: Abstract 125.
Deaney NB. Vogel R, Vandenburg MJ, et al. Norfloxacin in acute urinary tract infection. Practitioner 1984;228:111–7.
Vogel R, Deaney NB, Round EM, et al. Norfloxacin, amoxycillin, co-trimoxazole and nalidixic acid. A summary of 3-day and 7-day therapy studies in the treatment of UTI. J Antimicrob Chemother 1984;13(suppl B):113–20.
Leigh DA, Emmanuel FX. The treatment ofPs. aeruginosa UTI with norfloxacin. J Antimicrob Chemother 1984;13(suppl B):85–8.
Haase DA, Harding GK, Thomson MJ, et al. Comparative trial of norfloxacin and co-trimoxazole in the treatment of women with localized, acute, symptomatic UTI and antimicrobial effect on periurethral and fecal microflora. Antimicrob Agents Chemother 1984;26:481–4.
Leigh DA, Smith EC, Marriner J. Comparative study using norfloxacin and amoxycillin in the treatment of complicated UTI in geriatric patients. J Antimicrob Chemother 1984;13(suppl B):79–83.
Watt B, Chait I, Kelsey MC, et al. Norfloxacin vs CTX in the treatment of uncomplicated UTI — a multi-centre trial. J Antimicrob Chemother 1984;13(suppl B):89–94.
Boerema J, Boll B, Muytjens H. et al. Efficacy and safety of ciprofloxacin in the treatment of patients with complicated UTI. J Antimicrob Chemother 1985;16:211–7.
Garrel JB, Thabaut A, Grossetète G, et al. Efficacy and safety of pefloxacin in male gonococcal urethritis. In: Spitzky KH, Karrer K, eds. Proceedings of the 13th International Congress of Chemotherapy, Vienna 1983. Vienna: Egermann, 1983: Abstract PS 4.6/4-10.
Guibert J, Boutelier R. Pefloxacin: clinical assessment in UTI. In: Spitzky KH, Karrer K, eds. Proceedings of the 13th International Congress of Chemotherapy, Vienna 1983. Vienna: Egermann, 1983: Abstract PS 4.6/4-12.
Rozenberg-Arska K, Dekker AW, Verhoef J. Ciprofloxacin for selective decontamination of the alimentary tract in patients with acute leukemia during remission induction treatment. J Infect Dis 1985;152:104–7.
Nord CE, Delin C, Bergan T, Johansen S. Kolstad IM, Thorsteinsson SB. The effect of ciprofloxacin on otopharyngeal and colon microflora. Res Clin Forums 1985;7:89–95.
Ishigama J. Discussion. Res Clin Forums 1985;7:107–13.
Eliopoulos GM, Moellering AE, Reiszner E, Moellering RC.In vitro activities of the quinolone antimicrobial agents A56619 and A56620. Antimicrob Agents Chemother 1985;28:514–20.
Anonymous. Ofloxacin, broad spectrum antibacterial agent. Proceedings from the 24th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington DC, October 8–10 1984. Tokyo: Excerpta Medica, 1985.